Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr & Marx SJ. Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism 2001 86 5658-5671. (doi:10.1210/jc.86.12.5658)
Marini F, Falchetti A, DelMonte F, Carbonell Sala S, Gozzini A, Luzi E &Brandi ML. Multiple endocrine neoplasia type 1. Orphanet Journal of Rare Diseases 2006 1 38-47. (doi:10.1186/1750-1172-1-38)
Lips CJ, Dreijerink MA, Valk GD & Höppener JW. Multiple endocrine neoplasia type 1 (MEN1). In Clinical Endocrine Oncology, 2nd edn, pp 504-514. Eds ID Hay & JAH Wass, New York: Wiley Blackwell, 2008.
Balogh K, Patocs A, Majnik J, Racz K & Hunyady L. Genetic screening methods for the detection of mutations responsible for multiple endocrine neoplasia type 1. Molecular Genetics and Metabolism 2004 83 74-81. (doi:10.1016/j.ymgme.2004.08.013)
Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL & Marx SJ. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997 276 404-407. (doi:10.1126/science.276.5311.404)
White ML & Doherty GM. Multiple endocrine neoplasia. Surgical Oncology Clinics of North America 2008 17 439-459. (doi:10.1016/j.soc.2007.12. 002)
Teh BT, Zedenius J, Kytola S, Skogseid B, Trotter J, Choplin H, Twigg S, Farnebo F, Giraud S, Cameron D, Robinson B, Calender A, Larsson C & Salmela P. Thymic carcinoids in multiple endocrine neoplasia type 1. Annals of Surgery 1998 228 99-105. (doi:10.1097/00000658-199807000-00015)
Gibril F, Chen YJ, Schrump DS, Vortmeyer A, Zhuang Z, Lubensky IA, Reynolds JC, Louie A, Entsuah LK, Huang K, Asgharian B & Jensen RT. Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. Journal of Clinical Endocrinology and Metabolism 2003 88 1066-1081. (doi:10.1210/jc.2002-021314)
Ferolla P, Falchetti A, Filosso P, Tomassetti P, Tamburrano G, Avenia N, Daddi G, Puma F, Ribacchi R, Santeusanio F, Angeletti G & Brandi ML. Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. Journal of Clinical Endocrinology and Metabolism 2005 90 2603-2609. (doi:10.1210/jc.2004-1155)
Goudet P, Murat A, Cardot-Bauters C, Emy P, Baudin E, du Boullay Choplin H, Chapuis Y, Kraimps JL, Sadoul JL, Tabarin A, Verges B, Carnaille B, Niccoli-Sire P, Costa A & Calender A. Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). World Journal of Surgery 2009 33 1197-1207. (doi:10.1007/s00268-009-9980-y)
Shepherd JJ. The natural history of multiple endocrine neoplasia type 1. Highly uncommon or highly unrecognized? Archives of Surgery 1991 126 935-952.
Dean PG, van Heerden JA, Farley DR, Thompson GB, Grant CS, Harmsen WS & Ilstrup DM. Are patients with multiple endocrine neoplasia type I prone to premature death?World Journal of Surgery 2000 24 1437-1441. (doi:10.1007/s002680010237)
van Heerden JA, Smith SL & Miller LJ. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type I. Surgery 1986 100 971-977. (Pubitemid 17223212)
Mignon M & Cadiot G. Diagnostic and therapeutic criteria in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Journal of Internal Medicine 1998 243 489-494. (doi:10.1046/j.1365-2796.1998.00287.x)
Cadiot G, Vuagnat A, Doukhan I, Murat A, Bonnaud G, Delemer B, Thiefin G, Beckers A, Veyrac M, Proye C, Ruszniewski P & Mignon M. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d'Etude des Neoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE). Gastroenterology 1999 116 286-293. (doi:10.1016/S0016-5085(99)70124-1)
Gibril F, Schumann M, Pace A & Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine 2004 83 43-83. (doi:10.1097/01.md.0000112297.72510.32)
Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C & Calender A. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. Journal of Clinical Endocrinology and Metabolism 2002 87 457-465. (doi:10.1210/jc.87.2.457)
Goudet P, Bonithon C, Costa A, Cadiot A, Baudin E, Murat A, Delemer B, Tabarin A, Lecomte P, Calender A & Endocrine Tumor Study Group (GTE). A multiple endocrine neoplasia type-1 observatory in French-speaking area. A tool from the Endocrine Tumor study Group (GTE). Annales d'Endocrinologie 2007 68 154-159. (doi:10.1016/j.ando.2006.11.003)
Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P, Niccoli P, Ménégaux F, Chabrier G, Borson- Chazot F, Tabarin A, Bouchard P, Delemer B, Beckers A & Bonithon-Kopp C. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World Journal of Surgery 2010 34 249-255. (doi:10.1007/s00268-009-0290-1)
Mignon M, Jaïs Ph, Cadiot G, Ben Yedder D & Vatier J. Clinical features and advances in biological diagnostic criteria for Zollinger-Ellison syndrome. In Endocrine Tumors of the Pancreas: Recent Advances in Research and Management, pp 223-239. Eds M Mignon & RT Jensen, Basel: Karger, 1995.
Hartemann-Heurtier A & Chanson Ph. Hypoglycémies chez l'adulte non diabétique. In Traité d'endocrinologie, pp 1106-1113. Eds Ph Chanson & J Young, Paris: Flammarion, 2007.
Lévy-Bohbot N, Merle C, Goudet P, Delemer B, Calender A, Jolly D, Thiéfin G, Cadiot G & Groupe des Tumeurs Endocrines. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterologie Clinique et Biologique 2004 11 1075-1081. (doi:10.1016/S0399- 8320(04)95184-6)
Giraud S, Zhang CX, Serova-Sinilnikova O, Wautot V, Salandre J, Buisson N, Waterlot C, Bauters C, Porchet N, Aubert JP, Emy P, Cadiot G, Delemer B, Chabre O, Niccoli P, Leprat F, Duron F, Emperauger B, Cougard P, Goudet P, Sarfati E, Riou JP, Guichard S, Rodier M, Meyrier A, Caron P, Vantyghem MC, Assayag M, Peix JL, Pugeat M, Rohmer V, Vallotton M, Lenoir G, Gaudray P, Proye C, Conte-Devolx B, Chanson P, Shugart YY, Goldgar D, Murat A & Calender A. Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. American Journal of Human Genetics 1998 63 455-467. (doi:10.1086/301953)
Falchetti A & Brandi ML. Multiple endocrine neoplasia type I variants and phenocopies: more than a nosological issue? Journal of Clinical Endocrinology and Metabolism 2009 94 1518-1520. (doi:10.1210/jc.2009-0494)
Turner JJ, Christie PT, Pearce SH, Turnpenny PD & Thakker RV. Diagnostic challenges due to phenocopies: lessons from multiple endocrine neoplasia type 1 (MEN1). Human Mutation 2010 31 1089-1101. (doi:10.1002/humu. 21170)
Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, Edwards CR, Heath DA, Jackson CE, Jansen S, Lips K, Monson JP, O'Halloran D, Sampson J, Shalet SM, Wheeler MH, Zink A & Thakker RV. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Quarterly Journal of Medicine 1996 89 653-669. (Pubitemid 26319017)
Schaaf L, Pickel J, Zinner K, Hering U, Höfler M, Goretzki PE, Spelsberg F, Raue F, von zur Mü hlen A, Gerl H, Hensen J, Bartsch DK, Rothmund M, Schneyer U, Dralle H, Engelbach M, Karges W, Stalla GK & Höppner W. Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1. Experimental and Clinical Endocrinology & Diabetes 2007 115 509-517. (doi:10.1055/s-2007-970160)
Goudet P, Peschaud F, Mignon M, Nicoli-Sire P, Cadiot G, Ruszniewski P, Calender A, Murat A, Sarfati E, Peix JL, Kraimps JL, Henry JF, Cougard P, Proye C & Groupe des Tumeurs Endocrines. Gastrinomas in multiple endocrine neoplasia type-1. A 127-case cohort study from the endocrine tumor group (ETG). Annales de Chirurgie 2004 129 149-155. (doi:10.1016/j.anchir.2003.11.013)
Machens A, Schaaf L, Karges W, Frank-Raue K, Bartsch DK, Rothmund M, Schneyer U, Goretzki P, Raue F & Dralle H. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clinical Endocrinology 2007 67 613-622. (doi:10.1111/j.1365-2265.2007.02934.x)
Vierimaa O, Ebeling TM, Kytola S, Bloigu R, Eloranta E, Salmi J, Korpi-Hyovalti E, Niskanen L, Orvola A, Elovaara E, Gynther A, Sane T, Valimaki M, Ignatius J, Leisti J & Salmela PI. Multiple endocrine neoplasia type 1 in Northern Finland; clinical features and genotype phenotype correlation. European Journal of Endocrinology 2007 157 285-294. (doi:10.1530/EJE-07-0195)
Norton JA, Cornelius MJ, Doppman JL, Maton PN, Gardner JD & Jensen RT. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study. Surgery 1987 102 958-966.
Faglia G. Epidemiology and pathogenesis of pituitary adenomas. Acta Endocrinologica 1993 129 1-5.
Schaller B. Gender-related differences in prolactinomas. A clinicopathological study. Neuro Endocrinology Letters 2005 26 152-159.
Fernandez A, Karavitaki N & Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clinical Endocrinology 2010 72 377-382. (doi:10.1111/j.1365-2265.2009.03667.x)
Poncin J, Stevenaert A & Beckers A. Somatic MEN1. Gene mutation does not contribute significantly to sporadic pituitary tumorigenesis. European Journal of Endocrinology 1999 140 573-576. (doi:10.1530/eje.0.1400573)
Kameya T, Tsukada T & Yamaguchi K. Recent advances in MEN1 gene study for pituitary tumor pathogenesis. Frontiers of Hormone Research 2004 32 265-291.
Goebel SU, Vortmeyer AO, Zhuang Z, Serrano J, Jensen RT & Lubensky IA. Identical clonality of sporadic gastrinomas at multiple sites. Cancer Research 2000 60 60-63. (Pubitemid 30058731)
Kawamura J, Shimada Y, Komoto I, Okamoto H, Itami A, Doi R, Fujimoto K, Kosugi S & Imamura M. Multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas in Japan. Oncology Reports 2005 14 47-52.
Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B, Kinzler KW, Hruban RH & Papadopoulos N. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011 331 1199-1203. (doi:10.1126/science.1200609)
Dreijerink KM, Mulder KW, Winkler GS, Höppener JW, Lips CJ & Timmers HT. Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Research 2006 66 4929-4935. (doi:10.1158/0008-5472.CAN- 05-4461)
